Clinical TrialAug 11, 2026, 04:04 PM
Erasca ERAS-0015 Shows Efficacy in PDAC; Advances to Registration Trials
AI Summary
Erasca, Inc. reported updated clinical data for ERAS-0015, highlighting compelling monotherapy efficacy in 2L+ KRAS G12X pancreatic ductal adenocarcinoma and favorable tolerability. The company plans to advance ERAS-0015 toward three potentially registration-enabling trials in pancreatic and lung cancers. Erasca also announced a successful upsized public offering in July 2026, raising $632.5 million, significantly strengthening its balance sheet. For Q2 2026, the company reported a net loss of $44.1 million and R&D expenses of $35.9 million.
Key Highlights
- ERAS-0015 showed 57% uORR8wk in 2L+ KRAS G12X PDAC in U.S. trial.
- ERAS-0015 is advancing toward three potentially registration-enabling trials.
- Completed upsized public offering raising $632.5 million in gross proceeds.
- Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026.
- Q2 2026 R&D expenses increased to $35.9 million from $21.2 million YoY.
- Q2 2026 Net Loss was $44.1 million, or $(0.14) per basic and diluted share.
- ERAS-4001 preliminary Phase 1 monotherapy data expected in H2 2026.
- Appointed Charles Fuchs, M.D., M.P.H., as president of research and development.
Price Impact
More from ERAS